We are live on ! Find out more
TG

TRV GP Portfolio holdings

AUM $18.9M
1-Year Est. Return 541.67%
This Fund
S&P 500
This Quarter Est. Return
-10.7%
1 Year Est. Return
+541.67%
3 Year Est. Return
+3,178.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$120M
AUM Growth
-$38.5M
Cap. Flow
-$25.4M
Cap. Flow %
-21.13%
Top 10 Hldgs %
100%
Holding
5
New
1
Increased
–
Reduced
1
Closed
1

Top Buys

1
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$28.9M

Top Sells

1
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$31.6M
2
KALA icon
KALA BIO
KALA
+$22.7M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RYTM icon
1
Rhythm Pharmaceuticals
RYTM
$7.28B
$87M 72.32%
2,981,437
-1,000,000
-25% -$31.6M
CNST
2
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$20.4M 16.98%
+3,034,083
New +$28.9M
CARM
3
DELISTED
Carisma Therapeutics
CARM
$10.4M 8.66%
242,080
– –
LRMR icon
4
Larimar Therapeutics
LRMR
$381M
$2.46M 2.04%
17,531
– –
KALA icon
5
KALA BIO
KALA
$15.7M
– –
-662
Closed -$22.7M

Similar funds

KA
KSL Advisors Denver, Colorado $16.1M AUM
FRGX
First Reserve GP XII Stamford, Connecticut $3.16M AUM 24.66% 1-Year Est. Return
DHRFI
DCM Hybrid RMB Fund International Menlo Park, California $35.3M AUM
SA
Silversage Advisors Irvine, California $2.41M AUM 46.55% 1-Year Est. Return
YECIP
YT Extraction Co Investment Partners New York $1.73M AUM
FFIM
Founders Fund II Management San Francisco, California $1.32M AUM
ES
Equitec Specialists Chicago, Illinois $708K AUM 25.27% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM

TRV GP's Q3 2018 Portfolio in Review

As of Q3 2018, TRV GP held 5 positions worth $120M, down 24% from $159M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

TRV GP withdrew a net $25.4M in Q3 2018, closing 1 position and reducing 1 holding. Its most notable exit was KALA BIO, an estimated $22.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, TRV GP opened a new position in Constellation Pharmaceuticals, Inc. worth $20.4M.

  • TRV GP's largest Q3 2018 buy was Constellation Pharmaceuticals, Inc.: 3,034,083 shares worth $20.4M.
  • TRV GP's biggest Q3 2018 reduction was Rhythm Pharmaceuticals, cutting an estimated $31.6M.
  • TRV GP fully exited KALA BIO in Q3 2018, selling an estimated $22.7M.
  • TRV GP's ten largest holdings make up 100% of its $120M portfolio in Q3 2018.
  • TRV GP opened 1 new position and closed 1 in Q3 2018.
  • TRV GP's portfolio value fell 24% quarter-over-quarter to $120M.

Based on TRV GP's 13F filing for Q3 2018, filed 29 Oct 2018.